PSS22 - Secukinumab Significantly Reduces Work Impairment and Indirect Costs Compared To Ustekinumab and Etanercept In The United Kingdom
Autor: | Warren, R, Halliday, A, Graham, CN, Gilloteau, I, Miles, L, Sherif, B, McBride, D |
---|---|
Zdroj: | In Value in Health October-November 2017 20(9):A804-A804 |
Databáze: | ScienceDirect |
Externí odkaz: |